![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » JUBILANT MAY UNVEIL A BID OF USD 500 MN FOR CAMBREX
JUBILANT MAY UNVEIL A BID OF USD 500 MN FOR CAMBREX
June 16, 2006
Jubilant Organosys seems to have identified the New Jersey based NYSE-listed life-sciences company, Cambrex, as one of its potential acquisition targets, as it looks for big buys in the US and Europe. The domestic integrated pharma player could unveil a bid with valuation more than USD 500 mn following a due diligence in the next 3-6 months.
Myiris
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct